Plavix

(clopidogrel)

ApprovedSmall molecule

Clopidogrel is a blood thinner that helps prevent blood clots from forming, which is used to reduce the risk of heart attacks and strokes in people with heart disease or who have recently had a stent placed in their arteries.[2] Plavix is currently approved and in use across 60 indications[4].[1]

Plavix is one of 768 small molecule programs targeting Arterial Occlusive Disease. It is currently in Approved.

Indications

481

Total Trials

Active Trials

767

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Arterial Occlusive DiseaseApproved

Brain AneurysmApproved

Chronic Obstructive Pulmonary DiseaseApproved

ThrombophiliaApproved

Intermittent Vascular ClaudicationApproved

Myocardial IschemiaApproved

Systemic Lupus ErythematosusApproved

Angina PectorisApproved

HemorrhageApproved

Arterial Occlusive DiseaseApproved

Approved

Brain AneurysmApproved

Approved

Chronic Obstructive Pulmonary DiseaseApproved

Approved

ThrombophiliaApproved

Approved

Intermittent Vascular ClaudicationApproved

Approved

Myocardial IschemiaApproved

Approved

Systemic Lupus ErythematosusApproved

Approved

Angina PectorisApproved

Approved

HemorrhageApproved

Approved

Showing 10 of 57 indications

Competition

Competitive Landscape

172 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Plavix

Sanofi

Approved

3 2

Uloric

Takeda

Preclinical

2 3

Sovaldi

Gilead

Preclinical

1 4

Glucotrol

Pfizer

Preclinical

1 5

Vemlidy

Gilead

Preclinical

1 6

Lorelco

Sanofi

Preclinical

1 7

Activase

Flomax

Januvia

ZZydus Therapeutics Inc.

Preclinical

1 10

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Clopidogrel

NCT05926271

Q2 2027

Post-ApprovalRecruiting

Percutaneous Coronary Intervention

NCT06228456

Q3 2027

Post-ApprovalNot yet recruiting

Stroke

NCT05910125

Q4 2027

Active, not recruiting

ART

NCT06807788

Post-ApprovalNot yet recruiting

Cerebral Small Vessel Disease

NCT07180472

Post-ApprovalRecruiting

Clopidogrel

NCT06402747

Clinical

Trials by Indication[1]

Clopidogrel40 trials

Bleeding Time Study With AZD6482, Clopidogrel and ASA

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00853450·28 enrolled

Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT01663038·60 enrolled

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02925923·100 enrolled

Show 37 more trials

COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS

Unknown status·SShenyang Northern Hospital·Phase 4·NCT02578537·60 enrolled

Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.

Completed·UUllevaal University Hospital·Phase 4·NCT00222261·1,001 enrolled

To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects

Completed· Astellas logo

Astellas·Phase 1·NCT01409616·100 enrolled

A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01603342·18 enrolled

VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel

Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 4·NCT01684813·65 enrolled

Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT03289520·877 enrolled

Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT01826175

Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fed Conditions

Completed·—·Phase 1·NCT01621763·68 enrolled

Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel

Completed·UUniversity of Southern Denmark·Phase 1·NCT01456546·31 enrolled

Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI

Unknown status·FFirst Hospital of China Medical University·Phase 4·NCT02233790·600 enrolled

Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02222987·14 enrolled

RIsk of Apoplexia Cerebri in CLOpidogrel Non-responders

Terminated·ZZealand University Hospital··NCT02093299·165 enrolled

Investigation of the Athero-Protective Effects of Clopidogrel

Completed·EEmory University·Phase 4·NCT01283282·48 enrolled

Ticagrelor Versus Clopidogrel in Carotid Artery Stenting

Completed·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT02677545·210 enrolled

Clopidogrel for Acute Ischaemia of Recent Onset

Completed·—·Phase 4·NCT02776540·188 enrolled

Clopidogrel Resistance and Embolism in Carotid Artery Stenting

Unknown status·SSamsung Medical Center·Phase 3·NCT02133989·86 enrolled

Recruiting·SSt. Antonius Hospital·Phase 2·NCT05926271·200 enrolled

Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial

Completed·—·Phase 4·NCT01113372·3,119 enrolled

Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers

Completed·RResearch Associates of New York, LLP·Phase 4·NCT00778193·125 enrolled

Clopidogrel and Response Variability Investigation Study 2

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00822666·109 enrolled

Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects

Unknown status·HHK inno.N Corporation·Phase 1·NCT06164834·48 enrolled

Clopidogrel Resistance and the Possibility of Its Affection

Temporarily not available·—··NCT00839345

Clopidogrel Versus Cilostazol on Vessels

Recruiting·SSeoul National University Bundang Hospital·Phase 4·NCT06402747·120 enrolled

Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.

Completed·FFirst Affiliated Hospital of Harbin Medical University·Phase 4·NCT03679091·36 enrolled

Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT00413608·140 enrolled

Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02262650·24 enrolled

Ticagrelor vs. Clopidogrel in Post PCI Patients

Completed·SShiraz University of Medical Sciences·N/A·NCT05858918·476 enrolled

Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT02560688·22 enrolled

Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI

Unknown status·SSheba Medical Center·Phase 3·NCT00889044·30 enrolled

Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects

Completed· Sanofi logo

Sanofi·Phase 1·NCT01123824·40 enrolled

Hip-Fracture Surgery on Patients in Clopidogrel Therapy

Completed·HHvidovre University Hospital··NCT02391883·356 enrolled

Prasugrel/Clopidogrel Maintenance Dose Washout Study

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT01014624·56 enrolled

Clopidogrel Pharmacogenetics (PGX) Bench to Bedside

Completed·UUniversity of Maryland, Baltimore·N/A·NCT01341600·18 enrolled

Clopidogrel Bioequivalence Study in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02185534·144 enrolled

Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding

Completed·—·Phase 4·NCT01806090·216 enrolled

CASTLE (Clopidogrel And Serum Troponin Level Elevation)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00716924·155 enrolled

The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance

Completed·—·Phase 3·NCT01032668·192 enrolled

Acute Coronary Syndrome17 trials

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00684203·120 enrolled

PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants

Completed·—·Phase 3·NCT01641510·70 enrolled

Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome

Completed·TThorax Centrum Twente··NCT03197298·2,062 enrolled

Show 14 more trials

Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT01107899·29 enrolled

Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome

Completed·UUniversity of Cologne·Phase 3·NCT01774838·49 enrolled

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02293395·3,037 enrolled

Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

Terminated·IIndiana University·Phase 4·NCT01612884·67 enrolled

Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management

Completed·SSeung-Jung Park·Phase 4·NCT02094963·800 enrolled

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00097591·13,619 enrolled

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

Completed·SSeung-Jung Park·Phase 2·NCT02319941·65 enrolled

Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly

Completed·SSt. Antonius Hospital·Phase 4·NCT02317198·1,011 enrolled

Clopidogrel Maintaining Dosage in Acute Coronary Syndrome After Drug Eluting Stent Implantation

Completed·SShenyang Northern Hospital·Phase 4·NCT00404053

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Terminated· AstraZeneca logo

AstraZeneca·Phase 4·NCT02052635·34 enrolled

Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial

Completed·LLMU Klinikum·Phase 4·NCT01959451·2,600 enrolled

Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome

Unknown status·—·Phase 4·NCT02446730·1,400 enrolled

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01603082·343 enrolled

A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00830960·720 enrolled

Coronary Artery Disease11 trials

Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.

Withdrawn·NNeil Kleiman, MD·Phase 4·NCT01011257

Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01107912·155 enrolled

Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 4·NCT02514642·30 enrolled

Show 8 more trials

The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT01260584·110 enrolled

Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor

Completed·UUniversity of Sao Paulo·Phase 2·NCT03039205·90 enrolled

Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease

Unknown status·SSt. Antonius Hospital·Phase 2/3·NCT05657041·80 enrolled

Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease

Completed·UUniversity of Florida·Phase 4·NCT02287909·87 enrolled

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

Completed·UUniversity of Florida·Phase 4·NCT04006288·90 enrolled

Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT02889549·60 enrolled

Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients

Completed· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 4·NCT01830491·162 enrolled

An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01118325·146 enrolled

Stroke7 trials

Cilostazol and Aspirin in Stroke and TIA

Completed·IIncheon St.Mary's Hospital·Phase 4·NCT06522113·378 enrolled

Cilostazol Stroke Prevention Study for Antiplatelet Combination

Completed·JJapan Cardiovascular Research Foundation·Phase 4·NCT01995370·1,884 enrolled

Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping

Completed·GGangnam Severance Hospital·Phase 4·NCT01174693·795 enrolled

Show 4 more trials

Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 4·NCT05910125·472 enrolled

Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591351·870 enrolled

MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention

Unknown status·UUniversity of Zurich·Phase 3·NCT03961334·620 enrolled

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03766581·2,366 enrolled

Myocardial Infarction6 trials

Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.

Withdrawn·RRegion Skane·Phase 3·NCT04069234

Effects of Ticagrelor on No-reflow in Patients With Acute ST-segment Elevation Myocardial Infarction

Unknown status·—·N/A·NCT02798874·240 enrolled

Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction

Completed·IInha University Hospital·Phase 4·NCT02026219·76 enrolled

Show 3 more trials

STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00623623·1,899 enrolled

Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56

Completed·TThe TIMI Study Group·Phase 2·NCT01235351·335 enrolled

Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction

Unknown status·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00976092·548 enrolled

69 more indications

Percutaneous Coronary Intervention6 trials

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00357968·201 enrolled

Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy

Unknown status·—·Phase 4·NCT01572129·240 enrolled

Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention

Completed·—·Phase 3·NCT01609647·76 enrolled

Show 3 more trials

Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention

Completed·PPeking Union Medical College Hospital·Phase 4·NCT02748330·40 enrolled

STEEL Percutaneous Coronary Intervention

Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 4·NCT02327624·180 enrolled

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

Recruiting·UUniversity of Florida·Phase 4·NCT06228456·50 enrolled

Antiplatelet5 trials

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

Completed·UUniversity of Texas Southwestern Medical Center·Phase 3·NCT02217501·159 enrolled

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00642811·98 enrolled

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

Completed·—·Phase 4·NCT01706510·28 enrolled

Show 2 more trials

P3AMI Antiplatelet Trial

Completed·TThe Royal Wolverhampton Hospitals NHS Trust·Phase 4·NCT02376283·87 enrolled

The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry

Completed·—·Phase 1·NCT04822363·112 enrolled

Antiplatelet Therapy5 trials

Antiplatelet Therapy in HIV

Completed·NNYU Langone Health·Phase 2·NCT02559414·55 enrolled

Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study

Completed·JJohannes Gutenberg University Mainz·Phase 4·NCT01700322·126 enrolled

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03698513·113 enrolled

Show 2 more trials

Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy

Unknown status·IImam Abdulrahman Bin Faisal University·Phase 4·NCT01823185·1,500 enrolled

Tailored Antiplatelet Therapy Following PCI

Completed·MMayo Clinic·Phase 4·NCT01742117·5,276 enrolled

Interaction5 trials

Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects

Completed· Sanofi logo

Sanofi·Phase 1·NCT01129388·72 enrolled

Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects

Completed·CChengdu Suncadia Medicine Co., Ltd.·Phase 1·NCT07040787·36 enrolled

An Interaction Study to Evaluate the Effect of Esomeprazole/Acetylsalicylic Acid on the Metabolism and Effect of Clopidogrel

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01210339·58 enrolled

Show 2 more trials

Clopidogrel/Aspirin Interaction Study

Completed·PPopulation Health Research Institute·Phase 4·NCT01102439·82 enrolled

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Completed·VViatris Innovation GmbH·Phase 1·NCT03430661·77 enrolled

Platelet Inhibition4 trials

Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis

Completed·UUppsala University·Phase 2·NCT00914368·450 enrolled

Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism

Unknown status·GGyeongsang National University Hospital·Phase 3·NCT00891670·80 enrolled

Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI

Unknown status·XXijing Hospital·Phase 4·NCT03006835·120 enrolled

Show 1 more trial

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Terminated· Novartis logo

Novartis·Phase 3·NCT00385138·5,364 enrolled

Platelet Function4 trials

Platelet Function Assessment for Atherothrombotic Patients

Unknown status·NNational Taiwan University Hospital·Phase 4·NCT00513149·150 enrolled

Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty

Completed·OOttawa Heart Institute Research Corporation·Phase 2/3·NCT00827346·100 enrolled

Reproducibility and Comparison of Platelet Function Assays With Aspirin and Clopidogrel (MK-0000-167)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01108588·15 enrolled

Show 1 more trial

Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile

Completed·UUniversiti Sains Malaysia·Phase 4·NCT05516784·80 enrolled

Ischemic stroke4 trials

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Terminated·UUniversity of California, San Francisco·Phase 3·NCT00991029·4,881 enrolled

Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT04142151·60 enrolled

Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke

Completed·KKafrelsheikh University·Phase 3·NCT06120725·580 enrolled

Show 1 more trial

Efficacy of Colchicine in Preventing Recurrent Stroke in the Patients With Acute Atherothrombotic Ischemic Stroke During Hospitalization

Unknown status·MMikhail Zykov·Phase 4·NCT06102720·200 enrolled

Endothelial Function3 trials

Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function

Unknown status·—·Phase 4·NCT02123004·350 enrolled

Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI

Completed·—·Phase 4·NCT02469740·61 enrolled

Effect of Ticagrelor on Endothelial Function

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 3·NCT01805596·45 enrolled

Coronary Artery Bypass3 trials

Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass

Unknown status·YYonsei University·Phase 4·NCT05166538·204 enrolled

Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study

Completed·HHamilton Health Sciences Corporation·Phase 3·NCT00330772·150 enrolled

Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery.

Completed·CCatharina Ziekenhuis Eindhoven·Phase 4·NCT00724880·135 enrolled

Thrombosis3 trials

CV004-007 Thrombosis Chamber Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02439190·42 enrolled

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

Completed·AAccumetrics, Inc.·N/A·NCT00645918·2,800 enrolled

Ex Vivo Human Thrombosis Chamber Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00935506·15 enrolled

Dual Antiplatelet Therapy3 trials

Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation

Completed·YYonsei University·Phase 4·NCT01192724·630 enrolled

Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets

Unknown status·BBloodworks·Phase 1/2·NCT03787927·60 enrolled

Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease

Completed·—·Phase 2·NCT04824911·376 enrolled

Atrial Fibrillation3 trials

Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation

Completed·UUMC Utrecht·Phase 2·NCT02565693·101 enrolled

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

Completed·—·Phase 4·NCT03463317·912 enrolled

Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI

Unknown status·LLudwig-Maximilians - University of Munich·Phase 4·NCT04981041·2,334 enrolled

Antithrombotic2 trials

Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI

Completed·CCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec·Phase 4·NCT02640794·222 enrolled

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

Recruiting·MMedical University of Gdansk·Phase 4·NCT04695106·2,230 enrolled

P2Y12 Inhibitor2 trials

Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving DAPT Undergoing Dental Procedure.

Unknown status·—·Phase 4·NCT03103685·428 enrolled

Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02617290·1,900 enrolled

Atherosclerosis2 trials

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

Recruiting·TTongji Hospital··NCT04847752·1,000 enrolled

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Recruiting·—·Phase 4·NCT06757764·2,340 enrolled

Atorvastatin2 trials

Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity

Completed·OOspedale Misericordia e Dolce·Phase 4·NCT01335048·50 enrolled

Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting

Unknown status·—·Phase 4·NCT01572623·150 enrolled

Efficacy and Safety2 trials

Efficacy and Safety Study of Ticagrelor

Unknown status·GGeneral Hospital of Chinese Armed Police Forces·Phase 3·NCT01812330·180 enrolled

Efficacy and Safety of Low-dose Ticagrelor

Completed·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT03381742·3,043 enrolled

Thrombolysis2 trials

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis

Withdrawn·—·Phase 4·NCT02048085

Ticagrelor for PCI Post Thrombolysis

Completed·UUnity Health Toronto·Phase 3·NCT01930591·140 enrolled

COVID-192 trials

Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

Completed·TThe TIMI Study Group·Phase 4·NCT04409834·390 enrolled

Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19

Completed·UUniversity of Milan·Phase 2·NCT04368377·5 enrolled

Effectiveness2 trials

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

Unknown status·NNorth Texas Veterans Healthcare System·Phase 4·NCT03150667·220 enrolled

Safety and Effectiveness of Ticagrelor in Patients Undergoing Carotid Stenting

Unknown status·—·Phase 1·NCT04091074·26 enrolled

Cerebral Small Vessel Disease2 trials

Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol

Not yet recruiting·FFirst Affiliated Hospital of Chengdu Medical College·Phase 4·NCT07180472·632 enrolled

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University··NCT06715007·300 enrolled

Platelet Reactivity2 trials

High On-treatment Platelet Reactivity Identified by Multiple Platelet Function Assay

Completed·WWuhan Asia Heart Hospital·N/A·NCT02699008·477 enrolled

Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)

Completed·TTaipei City Hospital··NCT03190005·35 enrolled

Treatment2 trials

Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy

Unknown status·SSt. Antonius Hospital·Phase 4·NCT05773989·88 enrolled

Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI

Completed·SStiftung Institut fuer Herzinfarktforschung·Phase 3·NCT01327534·63 enrolled

Major Cardiovascular Event1 trial

Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg

Completed·LLaboratoires Teriak·Phase 4·NCT03329261·167 enrolled

Percutaneous Coronary Intervention (PCI)1 trial

A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00059215·905 enrolled

ST Elevation Myocardial Infarction1 trial

Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis

Completed·HHospital do Coracao·Phase 3·NCT02298088·3,799 enrolled

Withdrawn·—·Phase 4·NCT02626169

Endotoxemia1 trial

Ticagrelor in Human Endotoxemia Response to Human Endotoxemia

Completed·RRadboud University Medical Center·N/A·NCT02612480·40 enrolled

Complication1 trial

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

Active, not recruiting·PPetrovsky National Research Centre of Surgery··NCT07358416·500 enrolled

Trial1 trial

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)

Active, not recruiting·RRigshospitalet, Denmark·N/A·NCT06449469·352 enrolled

Heart Transplantation1 trial

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Recruiting·OOttawa Heart Institute Research Corporation·Phase 3·NCT04770012·135 enrolled

Stent Implantation1 trial

Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

Terminated·CCHEOL WHAN LEE, M.D., Ph.D·Phase 4·NCT02494284·364 enrolled

Aneurysm1 trial

Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm

Completed·SSeoul National University Hospital·Phase 4·NCT03581409·198 enrolled

Anticoagulation1 trial

Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2/3·NCT05700266·1,180 enrolled

Coronary Revascularization1 trial

A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization

Unknown status·CCCRF Consulting Co., Ltd.·Phase 4·NCT01157455·1,900 enrolled

Platelet Aggregation1 trial

Effects of Edoxaban on Platelet Aggregation

Completed·UUniversity of Sao Paulo·Phase 2/3·NCT05122455·61 enrolled

Endothelial Dysfunction1 trial

Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation

Unknown status·KKiyuk Chang·Phase 4·NCT02379676·38 enrolled

Platelet Transfusion1 trial

Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01744288·258 enrolled

HIV infection1 trial

Targeting Platelets in Chronic HIV Infection

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT02578706·27 enrolled

ESRD1 trial

ONSET and OFFSET of Ticagrelor in ESRD

Completed·KKyunghee University Medical Center·Phase 3·NCT02163954·16 enrolled

Aortic Stenosis1 trial

Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 4·NCT02486367·60 enrolled

ART1 trial

Evaluation of Platelet Aggregability in Patients with Takayasu's Arteritis

Active, not recruiting·JJose Carlos Nicolau··NCT06807788·100 enrolled

Peripheral Arterial Disease1 trial

Edoxaban in Peripheral Arterial Disease

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT01802775·203 enrolled

Optical Coherence Tomography1 trial

Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel

Completed·NNanjing First Hospital, Nanjing Medical University·Phase 4·NCT02140801·352 enrolled

Transient Ischemic Attack1 trial

Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)

Completed·UUniversity of Calgary·Phase 2/3·NCT00109382·500 enrolled

Cholesterol1 trial

A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)

Recruiting·—·Phase 3·NCT07012629·1,652 enrolled

Chronic Kidney Disease1 trial

Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus

Completed·UUniversity of Florida·Phase 4·NCT03774394·61 enrolled

Outcome1 trial

Genotyping Influences Outcome of Coronary Artery Stenting

Completed·KKorea University Anam Hospital·N/A·NCT02707445·5,000 enrolled

Efficacy1 trial

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

Terminated· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01561950·91 enrolled

Intensive Care Unit1 trial

High "on Treatment" Platelet Reactivity in the Intensive Care Unit

Unknown status·MMedical University of Vienna·Phase 2·NCT02285751·200 enrolled

Tumors1 trial

Anti-platelet + Pembro for H&N Tumors

Completed·MMedical University of South Carolina·Phase 1·NCT03245489·20 enrolled

Diabetes Mellitus1 trial

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

Completed·UUniversity of Florida·Phase 4·NCT02548650·66 enrolled

Oral Anticoagulation1 trial

Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation

Unknown status·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00776633·614 enrolled

Perioperative Bleeding1 trial

Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT01960296·48 enrolled

Coronary Artery Lesions1 trial

Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions

Unknown status·XXijing Hospital·N/A·NCT05209412·370 enrolled

Atherosclerotic Plaque1 trial

Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation

Completed·CCHEOL WHAN LEE, M.D., Ph.D·Phase 4·NCT01905566·50 enrolled

Miscarriage1 trial

Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages

Unknown status·—·Phase 2/3·NCT01635426·32 enrolled

Vascular Disease1 trial

Anti-Inflammatory and Anti-Platelet Effect of Clopidogrel and Aspirin vs Aspirin Alone in Symptomatic Polyvascular Disease and in Patients With Multiple Recurrent Cardiovascular Events

Unknown status·—·Phase 3·NCT00775762·213 enrolled

Heart Attack1 trial

Which Therapy for Acute Heart Attacks? (The WEST Study)

Completed·UUniversity of Alberta·Phase 2/3·NCT00121446·300 enrolled

Peripheral Artery Disease1 trial

Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 4·NCT02121288

Antithrombotic Agents1 trial

OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT01955200·1,724 enrolled

Necrosis1 trial

ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"

Completed· Sanofi logo

Sanofi·Phase 2·NCT00360386·110 enrolled

Acute Myocardial Infarction1 trial

Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction

Completed·UUniversity of Zagreb·Phase 4·NCT04369534·120 enrolled

Antiretroviral Treatment1 trial

Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients

Terminated·JJules Desmeules·Phase 1·NCT03054207·21 enrolled

Transcatheter Aortic Valve Replacement1 trial

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Terminated· Bayer logo

Bayer·Phase 3·NCT02556203·1,653 enrolled

Renal artery stenosis1 trial

Zainidip in Renal Artery Stenosis

Completed·LLee's Pharmaceutical Limited·Phase 4·NCT02594410·149 enrolled

Unspecified4 trials

Simplified Anti-Thrombotic Therapy for FFR

Completed·OOdessa Heart Institute·N/A·NCT02384070·300 enrolled

A Pharmacodynamic Study With Ticagrelor in African American Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01523392·50 enrolled

Cilostazol and Endothelial Progenitor Cell

Unknown status·GGyeongsang National University Hospital·Phase 4·NCT04407312·60 enrolled

Show 1 more trial

Pharmacodynamic Study of Cilostazol in Healthy Volunteers

Completed· Otsuka logo

Otsuka·Phase 1·NCT02554721·77 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 17, 1997

PLAVIX

NDA NDA020839

Sources

References

[1]
ClinicalTrials.gov — 481 trial records for clopidogrel. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Plavix drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — clopidogrel compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for clopidogrel. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020839). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Purinergic Receptor P2Y12 Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Sanofi

Plavix

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Clopidogrel40 trials

Acute Coronary Syndrome17 trials

Coronary Artery Disease11 trials

Stroke7 trials

Myocardial Infarction6 trials

Percutaneous Coronary Intervention6 trials

Antiplatelet5 trials

Antiplatelet Therapy5 trials

Interaction5 trials

Platelet Inhibition4 trials

Platelet Function4 trials

Ischemic stroke4 trials

Endothelial Function3 trials

Coronary Artery Bypass3 trials

Thrombosis3 trials

Dual Antiplatelet Therapy3 trials

Atrial Fibrillation3 trials

Antithrombotic2 trials

P2Y12 Inhibitor2 trials

Atherosclerosis2 trials

Atorvastatin2 trials

Efficacy and Safety2 trials

Thrombolysis2 trials

COVID-192 trials

Effectiveness2 trials

Cerebral Small Vessel Disease2 trials

Platelet Reactivity2 trials

Treatment2 trials

Major Cardiovascular Event1 trial

Percutaneous Coronary Intervention (PCI)1 trial

ST Elevation Myocardial Infarction1 trial

Staphylococcus Aureus Bacteremia1 trial

Cerebrovascular Event1 trial

Inflammation1 trial

Endotoxemia1 trial

Complication1 trial

Trial1 trial

Heart Transplantation1 trial

Stent Implantation1 trial

Aneurysm1 trial

Anticoagulation1 trial

Coronary Revascularization1 trial

Platelet Aggregation1 trial

Endothelial Dysfunction1 trial

Platelet Transfusion1 trial

HIV infection1 trial

ESRD1 trial

Aortic Stenosis1 trial

ART1 trial

Peripheral Arterial Disease1 trial

Optical Coherence Tomography1 trial

Transient Ischemic Attack1 trial

Cholesterol1 trial

Chronic Kidney Disease1 trial

Outcome1 trial

Efficacy1 trial

Intensive Care Unit1 trial

Tumors1 trial

Diabetes Mellitus1 trial

Oral Anticoagulation1 trial

Perioperative Bleeding1 trial

Coronary Artery Lesions1 trial

Atherosclerotic Plaque1 trial

Miscarriage1 trial

Vascular Disease1 trial

Heart Attack1 trial

Peripheral Artery Disease1 trial

Antithrombotic Agents1 trial

Necrosis1 trial

Acute Myocardial Infarction1 trial

Antiretroviral Treatment1 trial